CD133在骨髓增生异常综合征患者中的表达及临床意义  

Expression of CD133 in the bone marrow of patients with myelodysplastic syndrome and its clinical significance

作　　者：钟立业[1,2] 杜欣[2] 耿素霞[2] 翁建宇[2] 郑海涛[1] 吴穗晶[1,2] 李扬秋[1] 

机构地区：[1]暨南大学医学院血液病研究所,广东广州510632 [2]广东省医学科学院/广东省人民医院血液科,广东广州510080

出　　处：《南方医科大学学报》2011年第5期854-855,863,共3页Journal of Southern Medical University

基　　金：十一五国家科技支撑计划项目(2008BAI61B02);中央高校基本科研业务专项资金(21610603)

摘　　要：目的探讨骨髓增生异常综合征(MDS)患者骨髓中CD133的表达及其临床意义。方法应用流式细胞仪采用直接免疫荧光标记法,分别测定31例难治性贫血伴幼稚细胞增多(RAEB)、10例难治性血细胞减少伴多系发育异常(RCMD)以及11例再生障碍性贫血患者骨髓中CD133+细胞和CD34+/CD38-细胞比例,对比分析CD133及CD34/CD38在不同亚型MDS中的表达及临床意义。结果在RAEB型MDS患者骨髓有核细胞中,CD133阳性细胞平均占6.75%,RCMD患者平均占1.41%,而再生障碍性贫血对照组占2.70%,RAEB组显著高于其他两组(P<0.05);再障对照组与RCMD组之间无显著性差异(P>0.05);CD34+/CD38-细胞比例在3组中均小于1%,统计学上无显著性差异(P>0.05)。结论 CD133在MDS的进展类型RAEB患者骨髓细胞中高表达,CD133有助于RAEB分型诊断;而CD34+/CD38-标记在MDS分型诊断中并无价值。Objective To investigate the expression of CD133 in the bone marrow of patients with myelodysplastic syndrome（MDS） and explore its clinical significance. Methods The expression of CD133 and CD34/CD38 in the bone marrow was detected using flow cytometry in 31 cases of refractory anemia with excess blasts（RAEB） ,10 cases of refractory cytopenia with multilineage dysplasia（RCMD） and 11 cases of aplastic anemia（AA） . Results The percentage of CD133-expressing cells was 6.75% in patients with RAEB,significantly higher than that in patients with RCMD（1.41%） and AA（2.70%） （P0.05）;the percentage of CD133-positive cells were similar between the latter two patient groups（P0.05） . The percentage of CD34＋/CD38-cells was similar in the 3 groups（P0.05） ,all lower than 1%. Conclusions Advanced MDS patients are characterized by an increase of CD133-expressing cells,suggesting the value of CD133 in the diagnosis of RAEB. CD34＋/CD38-cells do not show a significant value in the diagnosis of MDS.

关 键 词：骨髓增生异常综合征 CD133 流式细胞术 

分 类 号：R551.3[医药卫生—血液循环系统疾病]